Previous 10 | Next 10 |
Generic versions of a fish oil supplement proven to help reduce the risk of heart attacks took a big step toward pharmacy shelves on Thursday. A patent ruling that unravels Amarin 's (NASDAQ: AMRN) market exclusivity for Vascepa has been upheld by the U.S. Court of Appeals for the Federal Cir...
Amarin ( AMRN -3.7% ) is not yet admitting defeat in its patent infringement litigation against would-be generic Vascepa competitors Dr. Reddy's Laboratories ( RDY -0.2% ) and Hikma Pharmaceuticals. More news on: Amarin Corporation plc, Dr. Reddy's Laboratories Limited, Healthcare ...
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today provided an update following the decision by the U.S. Court of Appeals for the Federal Circuit in the company’s ongoing patent litigation. The Court upheld the March r...
Amarin's (NASDAQ: AMRN ) bid to revive patents on heart treatment Vascepa has failed, with a U.S. Court of Appeals - just one day after hearing arguments - has affirmed the previous trial court ruling . More news on: Amarin Corporation plc, Healthcare stocks news, Stocks on the move, ...
Amarin reports positive data for Vascepa Amarin Corporation plc ( AMRN ) provided new supporting data about the potential of its flagship product Vascepa in treating patients with persistent cardiovascular risk. Vascepa is the first and only agent analyzed on top of statin therapy report...
Shares of the mid-cap biopharma Amarin (NASDAQ: AMRN) plummeted by as much as 31% Wednesday on over 10 times the normal daily volume. The drugmaker's shares were tanking today in response to an appeals hearing over the patents for its heart medication Vascepa. Amarin's shares bounced ...
Gainers: Corcept Therapeutics (NASDAQ: CORT ) +35% . More news on: Corcept Therapeutics Incorporated, Vera Bradley, Inc., NanoViricides, Inc., Stocks on the move, , Read more ...
Amarin (NASDAQ: AMRN ) is down 10% premarket on robust volume in apparent reaction to reports that judges have been assigned in its appeal of an adverse ruling by a Nevada court opening the gate for generic versions of Vascepa (icosapent ethyl). More news on: Amarin Corporati...
Amarin Corporation plc ( AMRN ) came across our desk as a potential candidate for covered calls or naked put purposes. We state this because the biotech stock is trading at just over $7 (low-priced stock), has buckets of volatility and is liquid. Before we get into the strategies and why Ama...
VASCEPA is the first and only agent studied on top of statin therapy reported to exhibit coronary plaque regression in hypertriglyceridemic patients VASCEPA in REDUCE-IT® cardiovascular outcomes study achieved statistical significance for primary and secondary endpoints at predef...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...